Overexpression of MYC binding protein promotes invasion and migration in gastric cancer

Gong,Lijie; Xia,Yingjie; Qian,Zhenyuan; Shi,Ji; Luo,Jungang; Song,Guangyuan; Xu,Ji; Ye,Zaiyuan

doi:10.3892/ol.2018.7944

Overexpression of MYC binding protein promotes invasion and migration in gastric cancer

Authors:
- Lijie Gong
- Yingjie Xia
- Zhenyuan Qian
- Ji Shi
- Jungang Luo
- Guangyuan Song
- Ji Xu
- Zaiyuan Ye
View Affiliations

Affiliations: Department of Gastrointestinal and Pancreatic Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310000, P.R. China, Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310000, P.R. China, Department of Breast and Thyroid Surgery, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang 310000, P.R. China, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310000, P.R. China
Published online on: February 2, 2018 https://doi.org/10.3892/ol.2018.7944
Pages: 5243-5249

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) is the second leading cause of cancer‑associated mortality worldwide. Although the mortality rate of patients with GC has improved, it remains a significant health issue. The MYC proto‑oncogene protein serves key roles in cellular proliferation, differentiation, transformation and apoptosis. Previous studies have identified the abnormal expression of MYC‑binding protein (MYCBP) during tumorigenesis in multiple types of cancer. Furthermore, evidence demonstrates that the abnormal expression of MYCBP contributes to the invasion and migration of human cancer types, including colon cancer and glioma; however, its inﬂuence on GC remains unclear. In the present study, the expression of MYCBP in GC cells and tissues was analyzed by reverse transcription‑quantitative polymerase chain reaction. Additionally, GC cell lines were transfected with small interfering RNAs against MYCBP or lymphoid enhancer‑binding factor 1 (LEF‑1) and assessed by in vitro transwell migration and invasion assays. The results indicated that the expression of MYCBP in GC cells and tissues was markedly increased compared with a normal gastric epithelial cell line and adjacent normal gastric mucosal tissues, respectively. Furthermore, MYCBP downregulation notably inhibited the metastatic capacity of GC cells, and LEF‑1 knockdown was found to downregulate the expression of MYCBP. On the basis of the findings of the present study, MYCBP may be a direct target of the β‑catenin/LEF‑1 pathway via binding LEF‑1, and could potentially be used as a biomarker for the diagnosis and prognosis of GC.

View Figures

View References

1	Casaretto L, Sousa P and Mari J: Chemotherapy versus support cancer treatment in advanced gastric cancer: A meta-analysis. Braz J Med Biol Res. 39:431–440. 2006. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Zhang J, Zhan Z, Wu J, Zhang C, Yang Y, Tong S, Sun Z, Qin L, Yang X and Dong W: Association among polymorphisms in EGFR gene exons, lifestyle and risk of gastric cancer with gender differences in Chinese Han subjects. Plos One. 8:e592542013. View Article : Google Scholar : PubMed/NCBI
4	Xie Y, Zhi X, Su H, Wang K, Yan Z, He N, Zhang J, Chen D and Cui D: A novel electrochemical microfluidic chip combined with multiple biomarkers for early diagnosis of gastric cancer. Nanoscale Re Lett. 10:4772015. View Article : Google Scholar
5	Buiatti E, Palli D, Decarli A, Amadori D, Avellini C, Bianchi S, Bonaguri C, Cipriani F, Cocco P, Giacosa A, et al: A case-control study of gastric cancer and diet in Italy: II. Association with nutrients. Int J Cancer. 48:369–374. 2010. View Article : Google Scholar
6	Shi Y and Zhou Y: The role of surgery in the treatment of gastric cancer. J Surg Oncol. 101:687–692. 2010. View Article : Google Scholar : PubMed/NCBI
7	Dang CV: The interplay between MYC and HIF in the Warburg effect. Ernst Schering Found Symp Proc. pp. 1–53. 2007;
8	Rabbitts PH, Watson JV, Lamond A, Forster A, Stinson MA, Evan G, Fischer W, Atherton E, Sheppard R and Rabbitts TH: Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. Embo J. 4:2009–2015. 1985.PubMed/NCBI
9	Pelengaris S and Khan M: The many faces of c-MYC. Arch Biochem Biophys. 416:129–136. 2003. View Article : Google Scholar : PubMed/NCBI
10	Okuyama H, Endo H, Akashika T, Kato K and Inoue M: Downregulation of c-MYC protein levels contributes to cancer cell survival under dual deficiency of oxygen and glucose. Cancer Res. 70:10213–10223. 2010. View Article : Google Scholar : PubMed/NCBI
11	Mai S and Mushinski JF: c-MYC-induced genomic instability. J Environ Pathol Toxicol Oncol. 22:179–199. 2003. View Article : Google Scholar : PubMed/NCBI
12	Dang CV: MYC on the path to cancer. Cell. 149:22–35. 2012. View Article : Google Scholar : PubMed/NCBI
13	Hu D, Wu J, Tang X, Hu F, Yang Y, Du J, Ye S and Zhang R: Molecular cloning and tissue distribution of a Schistosoma japonicum gene encoding AMY-1. Mol Med Rep. 4:1267–1271. 2011.PubMed/NCBI
14	Taira T, Maëda J, Onishi T, Kitaura H, Yoshida S, Kato H, Ikeda M, Tamai K, Iguchi-Ariga SM and Ariga H: AMY-1, a novel C-MYC binding protein that stimulates transcription activity of C-MYC. Genes Cells. 3:549–565. 1998. View Article : Google Scholar : PubMed/NCBI
15	Jung HC and Kim K: Identification of MYCBP as a beta-catenin/LEF-1 target using DNA microarray analysis. Life Sci. 77:1249–1262. 2005. View Article : Google Scholar : PubMed/NCBI
16	Chiurillo MA: Role of the Wnt/β-catenin pathway in gastric cancer: An in-depth literature review. World J Exp Med. 5:84–102. 2015. View Article : Google Scholar : PubMed/NCBI
17	Wu C, Zhuang Y, Jiang S, Liu S, Zhou J, Wu J, Teng Y, Xia B, Wang R and Zou X: Interaction between Wnt/β-catenin pathway and microRNAs regulates epithelial-mesenchymal transition in gastric cancer (Review). Int J Oncol. 48:2236–2246. 2016. View Article : Google Scholar : PubMed/NCBI
18	Sawa M, Masuda M and Yamada T: Targeting the Wnt signaling pathway in colorectal cancer. Expert Opin Ther Targets. 20:419–429. 2016. View Article : Google Scholar : PubMed/NCBI
19	Duchartre Y, Kim YM and Kahn M: The Wnt signaling pathway in cancer. Crit Rev Oncol Hematol. 99:141–149. 2015. View Article : Google Scholar : PubMed/NCBI
20	Wang H, Yan X, Ji LY, Ji XT, Wang P, Guo SW and Li SZ: miR-139 functions as an antioncomir to repress glioma progression through targeting IGF-1 R, AMY-1, and PGC-1β. Technol Cancer Res Treat. 16:497–511. 2017. View Article : Google Scholar : PubMed/NCBI
21	Byun E, Park B, Lim JW and Kim H: Activation of NF-κB and AP-1 mediates hyperproliferation by inducing β-catenin and c-Myc in Helicobacter pylori-infected gastric epithelial cells. Yonsei Med J. 57:647–651. 2016. View Article : Google Scholar : PubMed/NCBI
22	Washington K: 7th Edition of the AJCC cancer staging manual: Stomach. Ann Surg Oncol. 17:3077–3079. 2010. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Method. 25:402–408. 2001. View Article : Google Scholar
24	Furusawa M, Onishi T, Taira T, Iguchi-Ariga SM and Ariga H: AMY-1 is a trigger for the erythrocyte differentiation of K562 cells. Int J Oncol. 16:339–345. 2000.PubMed/NCBI
25	Sakamuro D and Prendergast GC: New Myc-interacting proteins: A second Myc network emerges. Oncogene. 18:2942–2954. 1999. View Article : Google Scholar : PubMed/NCBI
26	Dhru HD, McDonough Winslow WS, Armstrong B, Tuncali S, Eschbacher J, Kislin K, Loftus JC, Tran NL and Berens ME: Reciprocal activation of transcription factors underlies the dichotomy between proliferation and invasion of glioma cells. Plos One. 8:e721342013. View Article : Google Scholar : PubMed/NCBI
27	Jiang X, Hu C, Arnovitz S, Bugno J, Yu M, Zuo Z, Chen P, Huang H, Ulrich B, Gurbuxani S, et al: miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia. Nat Commun. 7:114522016. View Article : Google Scholar : PubMed/NCBI
28	Lin C, Yao E, Wang K, Nozawa Y, Shimizu H, Johnson JR, Chen JN, Krogan NJ and Chuang PT: Regulation of Sufu activity by p66β and Mycbp provides new insight into vertebrate Hedgehog signaling. Genes Dev. 28:2547–2563. 2014. View Article : Google Scholar : PubMed/NCBI
29	Liao X, Siu MK, Au CW, Wong ES, Chan HY, Ip PP, Ngan HY and Cheung AN: Aberrant activation of hedgehog signaling pathway in ovarian cancers: Effect on prognosis, cell invasion and differentiation. Carcinogenesis. 30:131–140. 2009. View Article : Google Scholar : PubMed/NCBI
30	Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, Karikari C, Alvarez H, Iacobuzio-Donahue C, Jimeno A, et al: Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res. 67:2187–2196. 2007. View Article : Google Scholar : PubMed/NCBI
31	Shimizu M, Cohen B, Goldvasser P, Berman H, Virtanen C and Reedijk M: Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer. Cancer Res. 71:277–286. 2011. View Article : Google Scholar : PubMed/NCBI
32	Raghu H, Gondi CS, Dinh DH, Gujrati M and Rao JS: Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch-1 receptor. Mol Cancer. 10:1302011. View Article : Google Scholar : PubMed/NCBI
33	Hashimoto A, Hashimoto S, Ando R, Noda K, Ogawa E, Kotani H, Hirose M, Menju T, Morishige M, Manabe T, et al: GEP100-Arf6-AMAP1-cortactin pathway frequently used in cancer invasion is activated by VEGFR2 to promote angiogenesis. PLoS One. 6:e233592011. View Article : Google Scholar : PubMed/NCBI
34	Sakamuro D and Prendergast GC: New Myc-interacting proteins: A second Myc network emerges. Oncogene. 18:2942–2954. 1999. View Article : Google Scholar : PubMed/NCBI
35	Hermeking H, Rago C, Schuhmacher M, Li Q, Barrett JF, Obaya AJ, O'Connell BC, Mateyak MK, Tam W, Kohlhuber F, et al: Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci USA. 97:pp. 2229–2234. 2000; View Article : Google Scholar : PubMed/NCBI
36	Delaunay S, Rapino F, Tharun L, Zhou Z, Heukamp L, Termathe M, Shostak K, Klevernic I, Florin A, Desmecht H, et al: Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer. J Exp Med. 213:2503–2523. 2016. View Article : Google Scholar : PubMed/NCBI
37	Schambony A and Wedlich D: Wnt-5A/Ror2 regulate expression of XPAPC through an alternative noncanonical signaling pathway. Dev Cell. 12:779–792. 2007. View Article : Google Scholar : PubMed/NCBI
38	Willert K and Jones KA: Wnt signaling: Is the party in the nucleus? Genes Dev. 20:1394–1404. 2006. View Article : Google Scholar : PubMed/NCBI